Table 1 Patient characteristics.

Age (years, range 9.0–58.8)

0.94^e

 0–9

-

1 (0.7)

 10–19

2 (6.1)

4 (2.8)

 20–29

14 (42.4)

56 (39.0)

 30–39

12 (36.4)

56 (39.0)

 40–49

5 (15.2)

21 (14.9)

 50–59

-

3 (2.1)

Sex

 Female/Male

19 (57.6)/14 (42.4)

93 (66.0)/48 (34.0)

0.22^f

Comorbidities^a

 Depression

1 (3.0)

6 (4.3)

 Obesity

1 (3.0)

4 (2.8)

 Asthma

-

5 (3.5)

 Bipolar disorder

2 (6.1)

2 (1.4)

 Anxiety disorder

-

4 (2.8)

 Crohn’s disease

1 (3.0)

2 (1.4)

 Hypertension

1 (3.0)

2 (1.4)

 Psoriasis

-

3 (2.1)

 Prior malignancy^b

1 (3.0)

1 (0.7)

 Diabetes mellitus

1 (3.0)

1 (0.7)

 Chronic renal disease

1 (3.0)

1 (0.7)

 Rheumatoid arthritis

1 (3.0)

1 (0.7)

 Prior deep vein thrombosis

-

2 (1.4)

 Thyrotoxicosis

-

2 (1.4)

 Ankylosing spondylitis

2 (6.1)

-

 Irritable bowel syndrome

-

2 (1.4)

 No comorbidity

24 (72.7)

98 (69.5)

Prior disease modifying treatment

 None

4 (12.1)

14 (9.9)

 Interferon

5 (15.2)

8 (5.7)

 Natalizumab

12 (36.4)

42 (29.8)

 Mitoxantrone

5 (15.2)

0

 Glatiramer acetate

4 (12.1)

5 (3.5)

 Intravenous immunoglobulin

1 (3.0)

1 (0.7)

 Fingolimod

0

13 (9.2)

 Dimethyl fumarate

0

66 (46.8)

 Teriflunomide

0

4 (2.8)

 Rituximab

2 (6.1)

44 (31.2)

 Alemtuzumab

0

4 (2.8)

Prior lines of treatment

2 IQR (1–3)

2 IQR (1–2)

0.72^e

 Naïve

4 (12.1)

14 (9.9)

 1

7 (21.2)

43 (30.5)

 2

14 (42.4)

42 (29.8)

 3

8 (24.2)

19 (13.5)

 4

0

14 (9.9)

 5

0

8 (5.7)

 6

0

1 (0.7)

EDSS at ASCT^c

4 IQR (3–6)

3 IQR (2–4)

0.002^e

 0–1.5

2 (6.1)

21 (14.9)

 2–3.5

11 (33.3)

77 (54.6)

 4–5.5

11 (33.3)

27 (19.1)

 6–6.5

6 (18.2)

10 (7.1)

 7–9.5

3 (9.1)

5 (3.5)

Gadolinium-enhancing lesions at ASCT ^d

22 (66.7)

62 (44.0)

0.02^f

 0

11 (33.3)

79 (56.0)

 1–9

5 (15.2)

40 (28.4)

 10–20

3 (9.1)

8 (5.7)

 >20

8 (24.2)

5 (3.5)

Years since MS diagnosis

3.8 ± 3.0

4.8 ± 4.7

0.67^e

ARR in the year prior to ASCT

3.1 ± 3.2

1.3 ± 1.3

0.002^e